Related Experiment Videos

Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist

R Haring1, D Gurwitz, J Barg

  • 1Israel Institute for Biological Research, Ness-Ziona.

Insights

M1-selective agonists like AF102B reduce amyloid precursor protein (APP) secretion more effectively than non-selective agonists in cultured cells. This suggests a potential therapeutic advantage for sustained reduction of cell-associated APP.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Amyloid precursor protein (APP) secretion is linked to specific receptors, including the m1 muscarinic acetylcholine receptor (m1AChR).
  • APP metabolism is implicated in neurological disorders, with reduced beta A4 amyloid production being a key outcome.
  • Understanding APP regulation via m1AChR is crucial for developing targeted therapeutic strategies.

Purpose of the Study:

  • To investigate the differential effects of M1-selective and non-selective muscarinic agonists on APP secretion and cell-associated levels.
  • To evaluate the potential of AF102B, an M1-selective agonist, for sustained reduction of cell-associated APP.

Main Methods:

  • Utilized m1AChR-transfected PC12 cells for experimental studies.
  • Measured secreted and cell-associated APP levels following stimulation with carbachol (non-selective) and AF102B (M1-selective) at different time points (5-60 min and 24 h).

Main Results:

  • AF102B stimulation resulted in approximately half the secreted APP levels compared to carbachol within 5-60 minutes.
  • Both carbachol and AF102B similarly decreased cell-associated APP levels after 24 hours of stimulation.
  • A smaller reduction in APP secretion was observed with 24-hour AF102B stimulation compared to carbachol, potentially explaining the sustained decrease in cell-associated APP.

Conclusions:

  • M1-selective agonists, such as AF102B, demonstrate a distinct short-term effect on APP secretion compared to non-selective muscarinic ligands.
  • AF102B may offer an advantage over non-selective muscarinic ligands for achieving a sustained reduction in cell-associated APP levels.
  • These findings support the potential therapeutic utility of M1-selective agonists in managing conditions related to APP metabolism.

Related Concept Videos